SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Keryx Biopharmaceuticals Inc. (KERX)

NEW YORK, Aug. 2, 2016

The investigation concerns whether Keryx and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On August 1, 2016, Keryx revealed that a "production-related issue" at the manufacturer will cause an interruption in the supply Auryxia® (ferric citrate) tablets.  Keryx admitted that "current inventories of Auryxia are not sufficient to ensure uninterrupted patient access."  Keryx also withdrew its 2016 financial guidance. Following this news, Keryx stock dropped $2.63 per share, or 35.78%, to close at $4.72 on August 1, 2016.

If you purchased Keryx shares or if you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/kerx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com